Technology evaluation: R-1549, Antisoma/Roche.
R-1549 (formerly known as pemtumomab), a murine monoclonal antibody (HMFG1) specific for the cancer antigen PEM and radiolabeled with yttrium-90, is under development by Antisoma and Roche as a potential treatment for ovarian and gastric cancer. In July 2003, enrollment for a phase III trial in ovarian cancer was completed.
Xing
Pei Xiang
PX
Austin Research Institute, Studley Rd, Heidelberg, Vic 3084, Australia. px.xing@ari.unimelb.edu.au
D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C469215:pemtumomab